This site is intended for health professionals only

Saturday 20 April 2019
Share |

Topic: Gastroenterology

April 4, 2019
Different models should be evaluated to overcome specific transition items such as barriers to successful outcomes, and poor compliance and complications, in order to improve quality of life for the future adult
Transition is defined as the purposeful, planned movement of adolescents and young adults from a child-centred to adult-oriented health care system.1
 
March 28, 2019
ARTEMIS data demonstrate that most patients exceeded what are considered to be protective levels well before a full year of treatment
Aimmune has announced that its Phase III European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (AR101 Trial in Europe Measuring oral Immunotherapy Success), met its primary efficacy endpoint. 
 
March 26, 2019
Results presented at ENDO 2019, the Endocrine Society's annual meeting
Researchers using the world's largest twin registry to study seven autoimmune diseases found the risk of developing the seven diseases is largely inherited, but that some diseases are more closely related than others.
 
March 20, 2019
One in four people with coeliac disease were previously misdiagnosed with IBS

With only 3% of British adults aware that the symptoms of IBS (irritable bowel syndrome) are also common symptoms of coeliac disease, Coeliac UK, is calling on greater awareness of the similarity of symptoms and urges anyone with IBS to ask their GP for a coeliac disease blood test, if they have not already had one.

March 18, 2019
44-week UNIFI data presented for the first time during plenary session at 14th Congress of the European Crohn’s and Colitis Organisation
Janssen has announced new data from the Phase III UNIFI maintenance study. 
 
March 18, 2019
Professor Evelien Dekker discusses the rising burden of colorectal cancer in Europe and the need for consistent and successful screening programmes across the continent
Colorectal cancer is Europe’s second biggest cancer killer, claiming the lives of nearly 200,000 people across the continent each year. Current trends predict that the burden of colorectal cancer could increase by 12% by 2020, affecting 502,000 Europeans a year by 2020.1
 
March 7, 2019
Researchers have found a compound that may treat inflammatory bowel disease without directly targeting inflammation
Researchers at Washington University School of Medicine in the USA have found a compound that may treat IBD without directly targeting inflammation. The compound tamps down the activity of a gene linked to blood clotting. They discovered that the gene, SERPINE-1, was turned on at sites of intestinal inflammation and damage, and blocking its activity reduces IBD symptoms in mice.1
 
March 4, 2019
Could dose de-escalation be an alternative strategy to decrease drug exposure, related risk, and treatment‐related costs while maintaining clinical remission in IBD?
The introduction of anti-tumour necrosis factor (anti-TNF) therapy in 1999 has revolutionised the management of inflammatory bowel disease (IBD). The TAXIT trial introduced widely therapeutic drug monitoring (TDM) to tailor anti-TNF therapy and optimise the limited treatments options more effectively, particularly supporting decisions around non-response, loss of response and dose intensification.1 
 
March 4, 2019
Iron deficiency anaemia is frequently seen in inflammatory bowel disease and is difficult to treat, partly because many patients are intolerant to traditional oral iron therapies
Shield Therapeutics and Norgine have announced positive results from the AEGIS Head-to-Head (H2H) clinical trial, which compared Feraccru® (ferric maltol), a novel oral iron replacement therapy, to Ferinject® (ferric carboxymaltose (FCM)), a market-leading intravenously delivered iron replacement therapy.1
 
February 28, 2019
The results of a recent international study may contribute to the development of new therapies for chronic inflammatory bowel disease
An international research group from the Cluster of Excellence "Precision Medicine in Chronic Inflammation" in Kiel and Charité - Universitätsmedizin Berlin has uncovered a critical mechanism that controls immune reactions against microorganisms in the intestine. The results have been published in Nature Immunology.1
 
Led by Prof Dr Alexander Scheffold, the group as has uncovered a critical mechanism that establishes the balance between immune system and microbiota.
February 27, 2019
The largest study ever to look at why an expensive and commonly used group of drugs fails in patients with Crohn’s disease has concluded that standardised drug doses are often too low

A UK-wide collaboration led by the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust, part-funded by Crohn’s & Colitis UK and Guts UK, and supported by the NIHR has concluded that trials are needed to investigate whether early personalised dosing, guided by blood level monitoring, might help reduce the rate of treatment failure.

February 26, 2019
A genetic discovery could make treatment for Crohn’s disease and ulcerative colitis safer, by identifying patients who are at risk of potentially deadly drug side effects

A ground-breaking and large-scale NHS research collaboration, led by the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust, has discovered a gene mutation that allows the identification of patients at risk of a drug side effect, allowing clinicians to tailor alternative treatments to these individuals.

February 18, 2019
According to a new statement from a panel of national and international experts in gastroenterology, inflammatory bowel disease (IBD) and other areas, interventional (or therapeutic) IBD endoscopy has an expanding role in the treatment of disease and of adverse events from surgery
A report from the panel, Role of interventional inflammatory bowel disease in the era of biologic therapy; a position statement for the Global Interventional IBD Group, was published in the February issue of GIE: Gastrointestinal Endoscopy.1
 
February 18, 2019
A recent study has suggested that immune cells in the bowel of people who suffer with coeliac disease are permanently replaced by a new subset of cells that promote inflammation
Immune cells in the bowel of people who suffer with coeliac disease are permanently replaced by a new subset of cells that promote inflammation, suggests a new study involving researchers at Cardiff University.1
 
This permanent 'immunological scarring' lays the foundation for the disease to progress and could have long-term implications for gut health in affected patients.
 
February 18, 2019
A new technique using patients' own modified cells to treat Crohn's disease has been proven to be effective in preclinical experiments, with a clinical trial of the treatment expected to start in the next six months
Researchers at the NIHR Guy's and St Thomas' Biomedical Research Centre (BRC) developed the technique by studying white blood cells taken from patients who have Crohn's disease, and comparing them to cells of healthy people. Their findings allowed cell therapy specialists in the BRC to develop a treatment involving taking patients' cells, and culturing them so that they behave more like cells from healthy people.
 
January 31, 2019
The funding will support projects based in Birmingham, Newcastle and Edinburgh and is part of Innovate UK’s partnership with the third sector on health research projects, bringing direct benefits to both patients and UK businesses
 
Coeliac UK, the national charity for people who need to live gluten free, has combined forces with Innovate UK, the UK’s innovation agency, to drive improvements worth £750,000 in the food technology, diagnostics and digital care industries.
 
January 15, 2019
The findings of a study published in Nature Medicine might inform research to develop microbiome-based therapies to prevent or treat food allergy
Scientists at the University of Chicago have found that gut microbes from healthy human infant donors transplanted into mice protected animals exposed to milk from experiencing allergic reactions, while gut microbes transplanted from infants allergic to milk did not.
 
The study, published in Nature Medicine,1 was supported in part by NIH’s National Institute of Allergy and Infectious Diseases. 
 
January 15, 2019
Sheffield Teaching Hospitals is one of 20 UK sites participating in a groundbreaking trial looking at whether an anti-sickness drug commonly given to patients having cancer treatments such as radiotherapy and chemotherapy could improve the lives of patients living with irritable bowel syndrome
Sheffield Teaching Hospitals NHS Foundation Trust has been named as one of 20 UK sites involved in a landmark trial assessing whether a drug commonly used to prevent nausea and sickness after surgery, radiotherapy or chemotherapy could help treat patients suffering with the agonising symptoms of irritable bowel syndrome.
 
January 7, 2019
If approved, ustekinumab will be the first interleukin (IL)-12/23 inhibitor licensed for the treatment of ulcerative colitis

Janssen has announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of Stelara® (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC).

Ustekinumab is a human monoclonal antibody that targets the interleukin (IL)-12 and IL-23 cytokines, which are believed to play an important role in the immune and inflammatory responses seen in immune-mediated diseases, such as UC and Crohn’s disease.1

December 17, 2018
There are scant data that describe how often pregnant women deliberately stop eating a specific food item in order to prevent future food allergies in their newborns
Pregnant women routinely swear off alcohol and tobacco to boost their chances of having a healthy baby. What about common food allergens like nuts and milk?
 
December 13, 2018
There is growing evidence that the composition of the microbiome is a promising predictive tool for disease and for patient response to therapy in conditions such as IBD, cancer and liver disease
BiomX Ltd, a microbiome company developing customised phage therapies,  has entered into a collaboration with Janssen Research & Development to utilise BiomX’s XMarker microbiome-based biomarker discovery platform. The XMarker platform will be used to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics.
 
The collaboration was facilitated by Johnson & Johnson Innovation Limited.
 
December 10, 2018
Men with inflamed guts are four to five times at risk for prostate cancer and are in need of more careful screening
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
 
This is the first report to show men with inflammatory bowel disease have higher than average PSA (prostate-specific antigen) values, and this group also has a significantly higher risk of potentially dangerous prostate cancer.
 
December 7, 2018
Researchers at the Karolinska Institutet in Sweden have published results showing that online cognitive behavioural therapy can be useful in treating gastrointestinal disorders in children when no physical cause can be found

Cognitive behavioural therapy (CBT) online can be useful in treating gastrointestinal disorders in children when no physical cause can be found.

This is the viewpoint of researchers at Karolinska Institutet in Sweden that is described in a new study published in the journal Clinical Gastroenterology and Hepatology.1

December 6, 2018
Nexvax2 is currently the only disease-modifying therapeutic in clinical development for patients with coeliac disease